Galapagos NV ADR (GLPG)

73.77
-2.31(-3.04%)
After Hours
73.77
0.00(0.00%)
- Real-time Data
  • Volume:
    1,081,235
  • Bid/Ask:
    73.77/79.95
  • Day's Range:
    73.11 - 75.31

GLPG Overview

Prev. Close
76.08
Day's Range
73.11-75.31
Revenue
-
Open
74.4
52 wk Range
70.77-214.36
EPS
-
Volume
1,081,235
Market Cap
4.9B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
257,841
P/E Ratio
-
Beta
-
1-Year Change
-64.42%
Shares Outstanding
-
Next Earnings Date
Aug 05, 2021
What is your sentiment on Galapagos NV ADR?
or
Market is currently closed. Voting is open during market hours.

Galapagos NV ADR News

Galapagos NV ADR Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Galapagos NV ADR Company Profile

Galapagos NV ADR Company Profile

Employees
1328

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.

Read More
  • buy now?
    0
    • they have 5 bil in cash. Cashburn should be -10% annually. + sales filgotinib + pipeline speculations + new aquired businesses (they are looking to take over other companies with revenu)  . i think this is way oversold.
      0
      • long-term head and shoulder pattern
        0
        • dead?
          2
          • GALAPAGOS is what we will see for all the markets soon, maybe end 21 but it will all come down
            5
            • whats's your prediction?
              0
          • Galapagos Enters November With Flair: New Revelation About Toledo Target Family https://pennystocks.news/galapagos-enters-november-with-flair-new-revelation-about-toledo-target-family-glpg/
            0
            • https://www.gilead.com/news-and-press/press-room/press-releases/2020/7/gilead-and-galapagos-announce-positive-european-chmp-opinion-for-jyseleca-filgotinib-for-the-treatment-of-adults-with-moderate-to-severe-rheumatoid
              0
              • Investor overreaction though. Besides, the main application of Filgotinib is not for ulcerative colitis (turnover approximately EUR 500 million) but for rheumatism (turnover EUR 5 BILLION). Great starting moment now.
                0
                • What does galapagos do?
                  0
                  • no google in your country?
                    3
                  • Rudi Lenie Google so hard... Investing.com so easy to get answer. Me no need to think
                    0
                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.